Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072903 · ClinicalTrials.gov registry record
The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 78
- Enrollment target
NCT01072903 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 78 participants.
The verdict
NCT01072903 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
Study Summary
The research project addresses the following hypotheses (A) the normal balance of beneficial and detrimental commensal intestinal bacteria is deranged in IBS, with selective alterations in clinically defined patient subsets i.e., diarrhea predominant IBS (D-IBS) and post-infectious IBS (PI-IBS); (B) these changes in intestinal microflora are associated with sub-clinical mucosal inflammation and activation of the mucosal immune system; and (C) activation of the mucosal immune system leads to alterations in gastrointestinal (GI) functions (i.e., motility and sensation) and functional symptoms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072903
The ClinicalTrials.gov registry entry for NCT01072903 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01072903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01072903 about?
NCT01072903 is a clinical study titled "The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)". The research project addresses the following hypotheses (A) the normal balance of beneficial and detrimental commensal intestinal bacteria is deranged in IBS, with selective alterations in clinically defined patient subsets i.e., diarrhea predominant IBS (D-IBS) and post-infectious IBS (PI-IBS); (B)...
What is the current status of trial NCT01072903?
This trial is currently completed. The enrollment target is 78 participants. The study started on 2009-01. Estimated completion is 2012-07.
Who is sponsoring clinical trial NCT01072903?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.